LGND

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007 for Ligand Pharmaceuticals Inc. The company has transitioned from a commercial pharmaceutical entity to a research and development-focused biotech firm following the sale of its two major commercial product lines: the Oncology Product Line (sold to Eisai in October 2006) and the AVINZA Product Line (sold to King Pharmaceuticals in February 2007). Results for these sold lines are reported as "Discontinued Operations."

Key Financial Metrics

Note: The significant net income in 2007 is driven by a $310.4 million pre-tax gain on the sale of the AVINZA product line, recorded in discontinued operations.

Material Changes vs. Prior Period

• Revenue Shift: Continuing operations revenue dropped to $1.6 million (vs. $4.0 million in 2006) as the company no longer holds commercial product lines. Revenue now consists primarily of royalties from AVINZA ($1.4 million recognized in Q2 2007) and minor collaborative research fees.
• Asset Reduction: Total assets decreased by approximately $97.6 million due to the divestiture of commercial assets (inventory, acquired technology rights) and the payment of a $252.7 million special cash dividend.
• Restructuring Costs: The company incurred approximately $11.2 million in severance and restructuring charges in the first half of 2007 to reduce its workforce by approximately 244 positions following the asset sales.
• Shareholder Returns: In Q1 2007, the company paid a special cash dividend of $2.50 per share ($252.7 million total) and initiated a $100 million stock repurchase program, spending $25.4 million on buybacks in the first half of 2007.

Guidance, Outlook, and Risks

Outlook and Management Commentary: Management expects to fund operations through existing cash reserves and future royalty revenues from AVINZA sales. The company is refocusing on its R&D pipeline, including thrombopoietin agonists (LGD-4665) and collaborations with partners like GlaxoSmithKline (eltrombopag), Wyeth (bazedoxifene), and Pfizer (lasofoxifene). Management believes current liquidity is sufficient for at least the next twelve months.

Risks and Contingencies:

• SEC Investigation: An ongoing SEC investigation regarding the restatement of financial statements for 2002-2004 continues. The company has established a $10 million restricted indemnity fund for directors related to this matter.
• Legal Disputes: The Salk Institute for Biological Studies has filed for arbitration seeking at least $22 million in alleged royalties related to the Targretin asset sale. Ligand disputes these claims.
• Indemnification Obligations: Ligand retains liability for product returns and certain indemnification claims related to the sold Oncology and AVINZA lines. Specifically, Ligand remains liable to Organon for co-promotion termination payments if King defaults.
• Product Development Risk: Future profitability depends on the success of clinical trials and regulatory approvals for pipeline products, which are inherently uncertain.

Investor Verification Checklist

• AVINZA Royalty Performance: Verify the volume of AVINZA sales reported by King Pharmaceuticals to ensure projected royalty revenues (15% for the first 20 months post-sale) are being realized.
• Product Return Reserves: Monitor the adequacy of the $11.7 million reserve for AVINZA product returns and $4.9 million for Oncology returns, as higher-than-expected returns would impact discontinued operations.
• SEC Investigation Status: Track developments in the SEC investigation to assess potential fines, penalties, or further restatements.
• Salk Institute Arbitration: Review the outcome of the arbitration demand filed by the Salk Institute regarding Targretin royalties.
• R&D Pipeline Progress: Monitor clinical trial results for key candidates like LGD-4665 and partner products (eltrombopag, bazedoxifene, lasofoxifene) to gauge future revenue potential.